Company Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel.
It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Country | Israel |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Amir Reichman M.B.A., M.Sc. |
Contact Details
Address: Jerusalem Biopark, 2nd Floor, Hadassah Ein Kerem Campus Jerusalem, L3 00000 Israel | |
| Phone | 972-8-9302529 |
| Website | scinai.com |
Stock Details
| Ticker Symbol | SCNI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611747 |
| ISIN Number | US09073Q2049 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Amir Reichman M.B.A., M.Sc. | Chief Executive Officer and Director |
| Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Science Officer |
| Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Dalit Weinstein Fischer | Chief Technology Officer |
| Joshua E. Phillipson B.Sc., M.B.A. | Director of Communications and Investor Relations |
| Liat Halpert | Head of Business Development and Sales |
| Moran Ahdout Fruchter L.L.B. | Chief of Staff |
| Merav Kamensky | Head of Quality Control |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 16, 2024 | 6-K | Report of foreign issuer |
| Mar 12, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | EFFECT | Notice of Effectiveness |
| Feb 2, 2024 | UPLOAD | Filing |
| Jan 30, 2024 | F-3 | Filing |
| Jan 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 18, 2024 | 6-K | Report of foreign issuer |
| Jan 12, 2024 | D | Notice of Exempt Offering of Securities |